MACSF

COMMUNIQUÉS West-GlobeNewswire

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
25/07/2025
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to [...]
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
25/07/2025
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
25/07/2025
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations [...]
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
25/07/2025
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion [...]
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
25/07/2025
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
La Commission européenne approuve DARZALEX® (daratumumab) comme premier traitement autorisé pour les patients présentant un myélome multiple indolent à haut risque
25/07/2025
Cette approbation historique repose sur les résultats de l’étude de la Phase 3 AQUILA, qui ont démontré qu’un traitement de durée fixe par daratumumab permettait de réduire significativement de 51 pour cent le risque de [...]
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
25/07/2025
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced [...]
Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025
25/07/2025
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 second quarter earnings conference call on Thursday, August 7, 2025 at 8:30 a.m. ET [...]
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
25/07/2025
GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
25/07/2025
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
25/07/2025
Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or [...]
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
25/07/2025
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus [...]
Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica
25/07/2025
CRANSTON, R.I., July 25, 2025 (GLOBE NEWSWIRE) -- Nelipak ® Corporation (“Nelipak®”), a leading global provider of healthcare packaging solutions for medical device, diagnostic, pharmaceutical drug delivery, and other [...]
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
25/07/2025
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic [...]
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
25/07/2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy [...]
RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call
25/07/2025
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
25/07/2025
Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Approbation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ [...]
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
25/07/2025
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment [...]
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
25/07/2025
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observed Supports progression into Phase III development with the potential to [...]

Pages